Of all the symptoms kidney cancer can produce, blood in the urine — hematuria — is the one that matters most. It is the most common symptom, present in approximately 40 to 60 percent of kidney cancer patients at diagnosis. It is the symptom most likely to prompt a person to seek medical care. And it is the one that, when properly evaluated without delay, can lead to an early-stage diagnosis where curative treatment is most achievable.
Yet hematuria is also the symptom most frequently dismissed, delayed, or misattributed. Patients assume the blood came from a urinary tract infection — even when it is completely painless. Clinicians prescribe antibiotics without obtaining upper urinary tract imaging. The blood goes away on its own, reinforcing the belief that it was nothing serious, only to return weeks later when the tumor has grown. This pattern of hematuria, reassurance, recurrence, and eventual late diagnosis is preventable.
What Does Blood in Urine Look Like
Gross hematuria is visible to the naked eye. The urine may appear pink, bright red, dark red, brown, or tea-colored (described as “cola-colored” or “rust-colored”). Even urine that appears only slightly pink contains a medically meaningful amount of blood — as little as one milliliter of blood per liter of urine is enough to produce visible discoloration. Gross hematuria from an upper tract source (kidney or ureter) may produce worm-shaped blood clots — clots that have taken the shape of the ureter as they pass through it. The passage of a clot can cause acute, colicky pain (clot colic), resembling kidney stone pain. Bladder hematuria more typically produces amorphous clots that fill the bladder.
Microscopic hematuria is invisible to the naked eye and is detected only on urinalysis. The standard definition is ≥3 red blood cells per high-power field (RBCs/HPF) on properly collected midstream urine. Automated urine dipstick testing detects hemoglobin with high sensitivity but moderate specificity — a positive dipstick result should always be confirmed with microscopic urinalysis, as false positives occur with myoglobinuria, beet ingestion, and certain medications.
The intermittency pattern: Kidney cancer-related hematuria does not follow a consistent schedule. A patient may notice bright red urine for one or two days, then see completely normal urine for weeks or months before the bleeding recurs. This stop-start pattern is caused by the natural cycle of tumor vessel rupture and temporary hemostasis. The intermittency is not evidence of a self-resolving benign process — it is a characteristic of how tumors bleed, and each recurrence should be treated with the same urgency as the first episode.
In patients presenting with painless gross hematuria: urinary tract cancer is found in 10–20% of cases. Bladder cancer accounts for the majority; kidney cancer (RCC) accounts for roughly 5–10%. Either way — one in ten to one in five patients with painless blood in the urine has cancer. This is not a symptom to observe and monitor.
How Kidney Cancer Causes Blood in the Urine
The kidneys are highly vascular organs, and as an RCC tumor grows, it erodes the tiny blood vessels within and around it. When this erosion occurs adjacent to the collecting system — the calyces and renal pelvis through which urine flows — blood enters the urine directly. The primary mechanisms include:
- Direct tumor invasion of the collecting system: as the tumor grows toward the renal pelvis, it breaches the urothelium lining, allowing blood to mix directly with urine
- Arteriovenous fistula formation: abnormal connections between arteries and veins within the tumor create high-pressure bleeding points
- Tumor necrosis: large tumors outgrow their blood supply, with necrotic tissue eroding adjacent vessels
- Venous hemorrhage: tumor-associated venous structures are fragile and rupture-prone under normal blood flow pressure fluctuations
Not all kidney cancers produce hematuria. Tumors located in the outermost kidney cortex, growing away from the collecting system into the perirenal fat, may reach several centimeters without ever causing visible bleeding — which is why so many kidney cancers are found incidentally on imaging performed for other reasons.
Why Painless Hematuria Is the Most Dangerous Kind
The most important clinical principle in hematuria evaluation: painless gross hematuria is a malignancy until proven otherwise.
Most common causes of hematuria produce it in the context of other symptoms. A UTI causes burning urination, frequency, and urgency. A kidney stone causes severe colicky pain. When blood appears in the urine without any of these accompanying symptoms — no pain, no burning, no fever, no urgency — the likelihood that the cause is malignant increases substantially.
The danger is that painless hematuria feels less alarming. A patient with sudden severe flank pain and bloody urine will present to the emergency department that same evening. A patient who notices pink-tinged urine for two days with no pain may wait to see if it resolves, take leftover antibiotics, and delay the CT scan that would have found a 4 cm tumor. By the time they seek evaluation after the third recurrence six months later, the tumor may have grown significantly.
Other Causes of Blood in the Urine
Hematuria has a long differential diagnosis, and kidney cancer is not the most common cause — but it is among the most important causes to exclude:
Upper urinary tract: kidney stones (most common cause overall; typically painful), urinary tract infection / pyelonephritis, kidney cancer (RCC, urothelial carcinoma of the renal pelvis), IgA nephropathy (most common glomerular cause; brown tea-colored urine following URI; diagnosed by kidney biopsy), polycystic kidney disease (hematuria from cyst hemorrhage).
Lower urinary tract: bladder cancer (second most common malignant cause of hematuria, also typically painless), cystitis (bacterial, radiation-induced, interstitial), benign prostatic hyperplasia, prostate cancer, urethritis.
Systemic causes: Anticoagulant therapy (warfarin, rivaroxaban, apixaban) can cause hematuria — but anticoagulation use does not eliminate the need for structural evaluation. Anticoagulation lowers the threshold for bleeding from a lesion that may not have bled otherwise; the underlying structural abnormality still requires investigation. Exercise-induced hematuria resolves within 72 hours of stopping exercise and is a diagnosis of exclusion after structural causes are excluded.
Red Flags That Point to Kidney Cancer
When evaluating a patient with hematuria, several features increase the probability that kidney cancer is the cause:
- Age over 40 — vast majority of RCC diagnosed after 50
- Male sex — RCC twice as common in men
- Smoking history — substantially increases RCC risk
- Painless hematuria — absence of pain shifts differential toward malignancy
- No urinary symptoms — no dysuria, frequency, or urgency
- Negative urine culture — excludes UTI; mandates imaging
- Hematuria persisting after antibiotics — strong indication for CT urogram
- Recurrent episodes — each recurrence treated as the first, not confirmation of prior benign diagnosis
- Constitutional symptoms — weight loss, fatigue, new hypertension, or bone pain accompanying hematuria
How Blood in the Urine Is Evaluated
The American Urological Association (AUA) guideline provides a structured evaluation pathway:
- Urinalysis with microscopy: confirms blood is present (not a false positive); quantifies degree; evaluates for RBC casts suggesting glomerular origin
- Urine culture: if infection confirmed and treated, repeat urinalysis. If hematuria persists post-treatment, or no infection found, proceed to imaging
- CT urogram (abdomen and pelvis without and with IV contrast): gold standard for upper tract evaluation; identifies renal masses, urothelial tumors, stones, and structural abnormalities
- Cystoscopy: direct visualization of the bladder and urethra; recommended for all gross hematuria and risk-stratified microscopic hematuria; CT alone cannot exclude small or flat bladder tumors
- Urine cytology (add-on for high-risk): most useful for high-grade urothelial carcinoma; not sensitive for low-grade tumors or RCC
What to Do If You See Blood in Your Urine
Contact a physician the same day or visit an urgent care center. Do not wait to see if the blood goes away. Do not take antibiotics unless a culture has confirmed bacterial infection. Do not dismiss it as a likely UTI because you have had UTIs before. You are asking for: urinalysis with microscopy, urine culture, and a referral for CT urogram and urology consultation. None of these steps are invasive or overly expensive — and the information they provide is potentially life-saving.
For the full context on kidney cancer warning signs beyond hematuria, see our guide to kidney cancer symptoms. If the CT urogram reveals a renal mass, our complete guide to kidney cancer types, staging, and treatment covers the next steps. Our article on bladder cancer discusses how evaluation differs when the lower urinary tract is the source of bleeding. Blood in the urine is the body’s most consistent and actionable signal that something may be wrong in the urinary tract. One episode, painless, resolved on its own — is enough to see a doctor.
Sources: National Cancer Institute — Kidney Cancer | American Urological Association Guidelines | American Cancer Society — Kidney Cancer
Varicocele and Other Non-Urinary Presentations
While hematuria is the classic presentation of kidney cancer-related bleeding, not all kidney cancer bleeding events produce urine discoloration. A tumor that compresses or invades the left renal vein can cause a sudden-onset varicocele — an abnormal dilation of the scrotal venous plexus — in men. A right-sided varicocele (since the right spermatic vein drains directly into the IVC rather than the renal vein) or a new varicocele in a man over 40 that does not decompress when he lies flat should prompt renal and retroperitoneal imaging, even in the absence of hematuria.
Tumor bleeding into the perirenal space rather than the collecting system can cause sudden, severe flank pain and a visible or palpable flank mass (Wunderlich syndrome) — without producing any blood in the urine, because the bleeding is contained outside the kidney rather than within the urine-collecting structures. These cases are medical emergencies presenting with acute hemorrhage rather than urinary symptoms.
Hematuria Caused by Renal Pelvis Urothelial Carcinoma
Not all kidney-origin hematuria comes from renal cell carcinoma. Approximately 5 percent of kidney cancers arise from the urothelial cells lining the renal pelvis — the funnel-shaped structure at the center of the kidney that collects urine before it passes into the ureter. Renal pelvis urothelial carcinoma (also called transitional cell carcinoma of the renal pelvis) is biologically identical to bladder cancer, causes hematuria by the same mechanisms (tumor eroding through the urothelial lining into the lumen), and shares most of the same risk factors — most notably, smoking is an especially powerful risk factor for urothelial tumors at any site.
The distinction between RCC and urothelial carcinoma of the renal pelvis is important because their treatments differ substantially. RCC is treated with nephrectomy (partial or radical) and systemic therapies targeting the VEGF or immune checkpoint pathways. Renal pelvis urothelial carcinoma is treated like bladder cancer — with radical nephroureterectomy (removing the kidney, ureter, and bladder cuff) and platinum-based systemic chemotherapy for metastatic disease. The CT urogram can generally distinguish these two tumors by their enhancement pattern and location within the kidney, but occasionally a biopsy is needed for definitive diagnosis before treatment planning.
The Role of Urine Biomarkers Beyond Cytology
Standard urine cytology — examining cells shed into the urine — is a useful tool for detecting high-grade urothelial carcinoma but is not useful for detecting RCC, which rarely sheds recognizable malignant cells into the urine. Several newer urine biomarker tests have been developed to improve detection of bladder urothelial carcinoma specifically: NMP22, UroVysion FISH, ImmunoCyt, and the newer Cxbladder and EpiCheck assays. These are adjuncts to cystoscopy for bladder cancer surveillance, not replacements for the CT urogram that is needed to evaluate the upper urinary tract for kidney cancer.
For RCC specifically, there is no validated urine biomarker test available in routine clinical practice. The primary modality for detecting RCC remains imaging. Research into liquid biopsy approaches — detecting circulating tumor DNA (ctDNA) or circulating tumor cells in blood — is ongoing for kidney cancer and may eventually provide a blood-based early detection tool, but this has not yet reached clinical implementation.
When Hematuria Recurs After Kidney Cancer Treatment
Patients treated for kidney cancer — whether by partial nephrectomy, radical nephrectomy, or ablation — who subsequently develop hematuria face a specific and urgent clinical concern: is this hematuria from recurrence, a second primary tumor in the remaining kidney, or an unrelated new condition such as a UTI or stone? The answer requires prompt imaging rather than watchful waiting.
For patients who underwent partial nephrectomy, the remaining renal tissue can harbor local recurrence or develop new de novo tumors in the preserved kidney parenchyma. Hematuria from such recurrences may precede detection on scheduled surveillance imaging by weeks. For patients with hereditary kidney cancer syndromes (VHL, Birt-Hogg-Dubé, hereditary papillary RCC), bilateral tumor development is the expected natural history, and any new hematuria in a patient with a known syndrome should trigger unscheduled imaging of both kidneys, regardless of the timing of the last scheduled surveillance scan.
Patients who underwent radical nephrectomy with a single remaining kidney face an additional consideration: hematuria from the solitary kidney is particularly consequential because any surgical intervention in that kidney carries the risk of impairing the only functioning renal unit. These patients benefit from nephrology co-management, and treatment decisions for any newly identified mass must balance cancer control against preservation of renal function with great care.
Psychological Impact of Hematuria Discovery
The discovery of blood in the urine — particularly gross hematuria — is almost universally alarming to patients. The sudden appearance of visibly red or cola-colored urine, especially when completely painless and unexpected, generates significant anxiety. Patients often describe the experience as one of the most frightening moments in their lives, even before a diagnosis has been established.
This anxiety is clinically appropriate — it is the appropriate response to a potentially serious finding that deserves immediate evaluation. What is not appropriate is for that anxiety to paralyze a patient into inaction, or for the subsequent disappearance of visible blood to replace anxiety with false reassurance that prevents follow-through on the evaluation. The healthcare system’s goal is to channel hematuria-related anxiety productively: into a CT urogram appointment and a urology consultation, ideally within 1 to 2 weeks of the initial episode.
Patients who receive reassurance from a clinician that the hematuria is “probably a UTI” without imaging sometimes feel reluctant to push back or request further evaluation. Understanding the clinical principle that painless hematuria requires imaging regardless of the clinician’s initial presumption empowers patients to advocate for themselves — to say: “I understand you think this may be a UTI, but I’d like to also schedule a CT urogram given the hematuria, as I understand that’s the recommended pathway.” Most clinicians will agree; those who push back should be asked to document their reasoning.
Hematuria in the Context of Anticoagulant Therapy
A common clinical scenario: a patient on warfarin, rivaroxaban, or apixaban develops gross hematuria, and the clinician — and sometimes the patient — attributes it to the blood thinner. While anticoagulation does lower the threshold for bleeding from any source, the American Urological Association is explicit on this point: anticoagulation use does not eliminate the need for structural evaluation of hematuria. The reasoning is straightforward: anticoagulation makes it easier for an existing lesion to bleed, but it does not create a lesion. A patient on warfarin who develops hematuria may have a kidney tumor that their anticoagulation caused to bleed earlier than it otherwise would have — and that tumor needs to be found. Studies of anticoagulated patients with hematuria who underwent full evaluation have found urinary tract malignancy at rates comparable to non-anticoagulated patients. Anticoagulant use is not an explanation for hematuria — it is a possible amplifier of an underlying cause that still needs to be identified.
Grading the Urgency of Hematuria Evaluation
Not all hematuria presentations carry the same urgency, but all require evaluation. Clinical urgency stratification helps patients and clinicians prioritize appropriately:
Same-day evaluation indicated for: gross hematuria with passage of clots, particularly if the patient cannot urinate (urinary retention from clot burden); hematuria with acute severe flank pain and systemic illness; any neurological symptoms accompanying hematuria in a patient with a known history of kidney cancer (suggests possible metastasis).
Within 1 week evaluation indicated for: any episode of painless gross hematuria in an adult, even if spontaneously resolved; recurrent microscopic hematuria in a patient aged over 40 with risk factors (smoking, hypertension, obesity); gross hematuria that fails to resolve after completion of antibiotics prescribed for a presumed UTI.
Within 2–4 weeks evaluation indicated for: first-episode microscopic hematuria in a low-risk patient (young, non-smoker, no constitutional symptoms); microscopic hematuria without urinary symptoms in a patient without malignancy risk factors but with persistent findings on repeat urinalysis.
These time frames are not absolute — they represent reasonable clinical targets. Any patient uncertain about urgency should err on the side of earlier evaluation. The cost of an unnecessary CT urogram — measured in time, radiation dose, and expense — is incomparably smaller than the cost of a delayed kidney cancer diagnosis that allowed a resectable T1 tumor to progress to metastatic stage IV disease.
Living With the Uncertainty of an Incomplete Evaluation
After a first episode of hematuria, some patients complete the CT urogram and cystoscopy and have a normal result. A negative evaluation is reassuring but not a guarantee that kidney cancer is not present — small renal masses can be missed on CT if they are very small and located in positions that overlap with normal renal enhancement. The AUA recommends that patients with a negative evaluation but persistent or recurrent hematuria return for repeat evaluation rather than concluding that the episode was definitively benign.
For patients with a history of gross hematuria and a negative initial evaluation, any recurrence of blood in the urine should prompt repeat CT urogram and cystoscopy — not reassurance based on the prior normal study. The prior negative result tells you the tumor was not detectable at that time point; it does not tell you the same will be true six months later. This is the same principle that drives cancer screening programs generally: a negative screen is not immunity from disease, it is a snapshot in time.
Blood in the urine is actionable information. Do not dismiss it. Do not wait. Evaluate it promptly every single time it appears.